Key Takeaways From Pediatrix Medical Group Analyst Ratings
Portfolio Pulse from Benzinga Insights
Pediatrix Medical Group (NYSE:MD) has been analyzed by 4 analysts over the past three months, showing a range of perspectives from indifferent to somewhat bearish. The average 12-month price target has increased by 4.23% to $9.12. Analysts have adjusted their ratings and price targets, reflecting their response to recent developments. Despite positive revenue growth, the company faces challenges with profitability, ROE, and ROA.
August 15, 2024 | 4:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Pediatrix Medical Group has received mixed analyst ratings, with an average 12-month price target increase of 4.23% to $9.12. Despite positive revenue growth, the company faces challenges in profitability, ROE, and ROA.
The mixed analyst ratings and slight increase in price target suggest a neutral short-term impact. While revenue growth is positive, the company's challenges in profitability and returns may offset this, leading to a balanced outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100